Intensive Chemo-Radiotherapy With Peripheral Blood Progenitor Cell Rescue for Children With Advanced Neuroblastoma and Sarcomas
Completed · Phase 2
Conditions studied: Neuroblastoma, Ewings Sarcoma, Non-rhabdomyosarcoma Soft Tissue Sarcoma
In brief
The main purpose of this study is to determine the short and long term side effects of a very intensive treatment, which includes combinations of chemotherapy drugs followed by radiation therapy and two transplants supported by peripheral blood progenitor cells (stem cells), for children with advanced stage neuroblastoma and sarcomas.
Key facts
- Study ID
- NCT00165139
- Run by
- Dana-Farber Cancer Institute
- People needed
- 20
- Starts
- 1996-01-01
- Expected to finish
- 2009-02-01
- Last updated by the study team
- 2009-11-02
Who can join
Age: any, up to 19. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Previously untreated neuroblastoma Stage D > 365 days
- Previously untreated neuroblastoma Stage C at age > 365 days with n-myc amplification
- Previously untreated metastatic Ewings sarcoma/PNET
- Previously untreated non-rhabdomyosarcoma soft tissue sarcoma
- Confirmation of neuroblastoma at time of diagnosis by histologic specimen or with bone marrow specimen showing solid tumor. Confirmation of sarcoma by histologic specimen with evidence of metastatic disease be imaging study
- Patient 19 years of age or younger
- ANC > 1000
- Platelet count > 75,000
- SGOT < 2.5 x ULN
- Normal serum creatinine levels for age
You may not qualify if…
- Previous malignancy requiring nonsurgical treatment or bone marrow transplant.
- Relapsed disease
Where it is running
- Dana-Farber Cancer Institute — Boston, Massachusetts, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.